Vascular Medicine News

A single combined measure of three modifiable biomarkers in healthy women at midlife was predictive of 30-year risk for future cardiovascular events, according to new research presented at the European Society of Cardiology Congress.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

A polypill containing multiple blood pressure-lowering drugs may be an effective solution to addressing both uncontrolled hypertension and polypharmacy causing non-adherence to antihypertensive medications, speakers reported.

The timing of when a patient takes their blood pressure medication does not appear to matter for reducing CV event risk, according to two trials and a meta-analysis presented at the European Society of Cardiology Congress.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

In the ABYSS trial, a strategy of interrupting long-term beta-blocker treatment was not noninferior to continued use for the primary composite outcome of death, myocardial infarction, stroke or hospitalization for CV reasons.

Among patients admitted to the cardiac ICU, those engaging in recreational drug use were almost three times as likely to experience a repeat serious CV event within 1 year compared with nonusers, researchers reported.

Around 7 months after not meeting the Prescription Drug User Fee Act goal date for Yutrepia, the FDA has tentatively approved the drug for pulmonary arterial hypertension and pulmonary hypertension-associated interstitial lung disease.

Asian American, Native Hawaiian and Pacific Islander, or AA and NH/PI, communities continue to face significant racial disparities in health care access and outcomes across the United States, according to an expert.